Julie Rowin

Summary

Affiliation: University of Illinois at Chicago
Country: USA

Publications

  1. pmc Granulocyte macrophage colony-stimulating factor treatment of a patient in myasthenic crisis: effects on regulatory T cells
    Julie Rowin
    Department of Neurology and Rehabilitation, University of Illinois Medical Center, 912 South Wood Street, 855N, M C 796, Chicago, Illinois 60612, USA
    Muscle Nerve 46:449-53. 2012
  2. ncbi request reprint Late appearance of dropped head syndrome after radiotherapy for Hodgkin's disease
    Julie Rowin
    Department of Neurology and Rehabilitation, University of Illinois at Chicago, Neuropsychiatric Institute MC 796, Chicago, Illinois 60612 7330, USA
    Muscle Nerve 34:666-9. 2006
  3. doi request reprint Etanercept treatment in myasthenia gravis
    Julie Rowin
    University of Illinois at Chicago, Department of Neurology and Rehabilitation, Section of Neuromuscular Disease, Neuropsychiatric Institute, Chicago IL 60612 7330, USA
    Ann N Y Acad Sci 1132:300-4. 2008
  4. ncbi request reprint Mycophenolate mofetil in dermatomyositis: is it safe?
    J Rowin
    Department of Neurology and Rehabilitation, University of Illinois, Chicago, IL 60612 7330, USA
    Neurology 66:1245-7. 2006
  5. pmc Copper deficiency myeloneuropathy and pancytopenia secondary to overuse of zinc supplementation
    J Rowin
    University of Illinois at Chicago, Department of Neurology and Rehabilitation, Section of Neuromuscular Disease, Chicago, IL 60612, USA
    J Neurol Neurosurg Psychiatry 76:750-1. 2005
  6. pmc Functional defect in regulatory T cells in myasthenia gravis
    Muthusamy Thiruppathi
    Department of Neurology and Rehabilitation, College of Medicine, University of Illinois Hospital and Health Sciences System, Chicago, USA
    Ann N Y Acad Sci 1274:68-76. 2012
  7. ncbi request reprint Single fiber EMG as an outcome measure in myasthenia gravis: results from a double-blind, placebo-controlled trial
    Matthew N Meriggioli
    Department of Neurological Sciences, Rush University, Chicago, Illinois 60612, USA
    J Clin Neurophysiol 20:382-5. 2003
  8. ncbi request reprint Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study
    Matthew N Meriggioli
    Department of Neurological Sciences, Rush University and Rush Presbyterian St Luke s Medical Center, Chicago, Illinois 60612, USA
    Ann N Y Acad Sci 998:494-9. 2003
  9. pmc Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low/-) T cells in patients with myasthenia gravis
    Muthusamy Thiruppathi
    Department of Neurology and Rehabilitation, College of Medicine, University of Illinois Hospital and Health Sciences System, Chicago, IL 60612, USA
    Clin Immunol 145:209-23. 2012
  10. ncbi request reprint Etanercept treatment in corticosteroid-dependent myasthenia gravis
    J Rowin
    Section of Neuromuscular Disease, Department of Neurology and Rehabilitation, University of Illinois at Chicago, Chicago, IL 60612 7330, USA
    Neurology 63:2390-2. 2004

Collaborators

Detail Information

Publications22

  1. pmc Granulocyte macrophage colony-stimulating factor treatment of a patient in myasthenic crisis: effects on regulatory T cells
    Julie Rowin
    Department of Neurology and Rehabilitation, University of Illinois Medical Center, 912 South Wood Street, 855N, M C 796, Chicago, Illinois 60612, USA
    Muscle Nerve 46:449-53. 2012
    ..In this study we describe a patient with a prolonged myasthenic crisis refractory to conventional immunomodulatory therapy who was treated with GM-CSF (granulocyte macrophage colony-stimulating factor, sargramostim)...
  2. ncbi request reprint Late appearance of dropped head syndrome after radiotherapy for Hodgkin's disease
    Julie Rowin
    Department of Neurology and Rehabilitation, University of Illinois at Chicago, Neuropsychiatric Institute MC 796, Chicago, Illinois 60612 7330, USA
    Muscle Nerve 34:666-9. 2006
    ..This report adds to the increasing literature about the late neurological complications of radiation therapy and describes a previously unrecognized cause of dropped head syndrome...
  3. doi request reprint Etanercept treatment in myasthenia gravis
    Julie Rowin
    University of Illinois at Chicago, Department of Neurology and Rehabilitation, Section of Neuromuscular Disease, Neuropsychiatric Institute, Chicago IL 60612 7330, USA
    Ann N Y Acad Sci 1132:300-4. 2008
    ..A prospective clinical pilot trial of etanercept in corticosteroid-dependent autoimmune myasthenia gravis (MG) patients supports further study into etanercept as a treatment for MG...
  4. ncbi request reprint Mycophenolate mofetil in dermatomyositis: is it safe?
    J Rowin
    Department of Neurology and Rehabilitation, University of Illinois, Chicago, IL 60612 7330, USA
    Neurology 66:1245-7. 2006
    ..The disproportionately high rate of opportunistic infections in this group is considered...
  5. pmc Copper deficiency myeloneuropathy and pancytopenia secondary to overuse of zinc supplementation
    J Rowin
    University of Illinois at Chicago, Department of Neurology and Rehabilitation, Section of Neuromuscular Disease, Chicago, IL 60612, USA
    J Neurol Neurosurg Psychiatry 76:750-1. 2005
    ..An illustrative case of copper deficiency myeloneuropathy with pancytopenia is presented and the potential aetiologies and neurological manifestations of this deficiency state discussed...
  6. pmc Functional defect in regulatory T cells in myasthenia gravis
    Muthusamy Thiruppathi
    Department of Neurology and Rehabilitation, College of Medicine, University of Illinois Hospital and Health Sciences System, Chicago, USA
    Ann N Y Acad Sci 1274:68-76. 2012
    ..These findings indicate a clinically relevant T(reg) cell-intrinsic defect in immune regulation in MG that may reveal a novel therapeutic target...
  7. ncbi request reprint Single fiber EMG as an outcome measure in myasthenia gravis: results from a double-blind, placebo-controlled trial
    Matthew N Meriggioli
    Department of Neurological Sciences, Rush University, Chicago, Illinois 60612, USA
    J Clin Neurophysiol 20:382-5. 2003
    ..The authors conclude that immunomodulation by MM improves neuromuscular junction function in MG and that SFEMG may be a useful marker of early response in future therapeutic trials in autoimmune MG...
  8. ncbi request reprint Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study
    Matthew N Meriggioli
    Department of Neurological Sciences, Rush University and Rush Presbyterian St Luke s Medical Center, Chicago, Illinois 60612, USA
    Ann N Y Acad Sci 998:494-9. 2003
    ..Results of this pilot study are promising and suggestive of greater improvement in the patients who received MM compared to placebo...
  9. pmc Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low/-) T cells in patients with myasthenia gravis
    Muthusamy Thiruppathi
    Department of Neurology and Rehabilitation, College of Medicine, University of Illinois Hospital and Health Sciences System, Chicago, IL 60612, USA
    Clin Immunol 145:209-23. 2012
    ....
  10. ncbi request reprint Etanercept treatment in corticosteroid-dependent myasthenia gravis
    J Rowin
    Section of Neuromuscular Disease, Department of Neurology and Rehabilitation, University of Illinois at Chicago, Chicago, IL 60612 7330, USA
    Neurology 63:2390-2. 2004
    ..Six of the eight patients who completed the trial improved, based on quantitative measures of muscle strength and lowering of corticosteroid requirement...
  11. ncbi request reprint Treatment of myasthenia gravis with mycophenolate mofetil: a case report
    M N Meriggioli
    Rush Presbyterian St Luke s Medical Center, Section of Neuromuscular Disorders, Department of Neurological Sciences, Chicago, Illinois 60612, USA
    Muscle Nerve 23:1287-9. 2000
    ..In particular, its role as a steroid-sparing agent and as a drug to be used in combination immunotherapy in more severe or refractory cases of MG should be investigated...
  12. doi request reprint Broken heart syndrome in myasthenia gravis
    Vibhav Bansal
    Department of Neurology and Rehabilitation, University of Illinois Medical Center, Chicago, Illinois 60612, USA
    Muscle Nerve 44:990-3. 2011
    ....
  13. ncbi request reprint Fatigue and abnormal neuromuscular transmission in Kennedy's disease
    Matthew N Meriggioli
    Dept of Neurological Sciences, Rush University, 1725 W Harrison Street, Suite 1106, Chicago, IL 60612, USA
    Muscle Nerve 27:249-51. 2003
    ....
  14. doi request reprint Disseminated intravascular large-cell lymphoma with initial presentation mimicking Guillain-Barré syndrome
    Qin Li Jiang
    Department of Neurology, Jesse Brown VA Medical Center, Chicago, Illinois 60612, USA
    Muscle Nerve 42:133-6. 2010
    ..Autopsy revealed disseminated intravascular large-cell lymphoma. Intravascular large-cell lymphoma should be considered in the differential diagnosis of a rapidly evolving neuropathy associated with other organ involvement...
  15. ncbi request reprint Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability
    M N Meriggioli
    Department of Neurological Sciences, Rush University, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
    Neurology 61:1438-40. 2003
    ..Quantitative strength testing performed on the majority of patients before and after treatment also improved. Side effects to MyM were observed in 27% of patients but required discontinuation in only 6%...
  16. ncbi request reprint Electrodiagnostic significance of supramaximally stimulated A-waves
    J Rowin
    Department of Neurological Sciences, Section of Neuromuscular Disease, Rush Presbyterian St Luke s Medical Center, 1725 W Harrison St, Suite 1106, Chicago, Illinois 60612 3824, USA
    Muscle Nerve 23:1117-20. 2000
    ..We postulate that demyelination is the crucial underlying pathophysiologic correlate of the supramaximally stimulated A-wave...
  17. ncbi request reprint Predictive value of serum anti-C1q antibody levels in experimental autoimmune myasthenia gravis
    Erdem Tuzun
    Department of Microbiology and Immunology, University of Texas Medical Branch, 301 University Blvd, Galveston, TX 77555 1070, USA
    Neuromuscul Disord 16:137-43. 2006
    ..The serum levels of anti-C1q antibodies but not C1q, C3 and CIC are significantly correlated with the clinical severity in the experimental myasthenia mice. However, this correlation is not observed in myasthenia gravis patients...
  18. ncbi request reprint Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment
    Erdem Tuzun
    Department of Microbiology and Immunology, University of Texas Medical Branch, 301 University Blvd, Galveston, TX 77555 1070, USA
    J Autoimmun 24:261-8. 2005
    ..Moreover, patients with lower pre-treatment plasma IL-6 and IFN-gamma levels attained better clinical improvement following etanercept treatment...
  19. doi request reprint Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis
    Ted M Burns
    Department of Neurology, University of Virginia, Charlottesville, PO Box 800394, Charlottesville, Virginia 22908, USA
    Muscle Nerve 38:957-63. 2008
    ..Because the MG-QOL15 instrument can be quickly and easily administered and interpreted, it is a potential QOL measure for treatment trials and the clinical evaluation of patients with MG...
  20. doi request reprint Disease-specific measure of quality of life for myasthenia gravis
    Larry L Mullins
    University of Oklahoma Health Sciences Center, Department of Pediatrics, Oklahoma City, Oklahoma, USA
    Muscle Nerve 38:947-56. 2008
    ..Results from this study support the use of this new measure of QOL, both clinically and in treatment trials of MG...
  21. doi request reprint A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS
    Paul H Gordon
    Department of Neurology, Columbia University, New York, USA
    Amyotroph Lateral Scler 9:212-22. 2008
    ..This phase II design was efficient, leading to treatment selection after just 60 patients, and can be used in other phase II trials to assess different agents...